Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_00846 |
| Species: | Homo sapiens |
| Position : | chr15:45737631-45738460 |
| Year: | 2023 |
| Title: | Epigenetic reprogramming-induced guanidinoacetic acid synthesis promotes pancreatic cancer metastasis and transcription-activating histone modifications. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | pancreatic ductal adenocarcinoma |
| PMID: | 37370109 |
| MONDO: | MONDO:0005184 |
| Tissue: | pancreas |
| Tissue Ontology ID: | UBERON:0001264 |
| Cell Source: | Capan-1 |
| CVCL ID: | CVCL_0237 |
| Cell Type: | malignant cell |
| Cell Ontology ID: | CL:0001064 |
| Experiment Type: | Enhancer functional validation; chromatin interaction assay; Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| High Throughput Method: | In situ Hi-C; H3K27ac ChIP-seq; RNA-seq; CUT&RUN |
| Low Throughput Method: | CRISPRi (dCas9-KRAB); H3K27ac ChIP-qPCR; 3C-qPCR; RT-qPCR; CRISPRi; Luciferase reporter assay; ChIP; 3C; Western blot; In vivo phenotyping; Xenograft/xenotransplant |
| Target gene : | GATM |
| TF name : | NA |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|